Literature DB >> 26687981

Presymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.

Sebastian A Lewandowski1, Ingrid Nilsson2, Linda Fredriksson3,4, Peter Lönnerberg3, Lars Muhl2, Manuel Zeitelhofer2, Milena Z Adzemovic2, Susanne Nichterwitz5, Daniel A Lawrence4, Eva Hedlund5, Ulf Eriksson6.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with unknown origins. Neurodegeneration in ALS mouse models occurs together with signs of disrupted blood-spinal cord barrier (BSCB) and regressed capillary network, but the molecular pathways contributing to these vascular pathologies remain unknown. We show that motor neurons of human sporadic ALS patients (n = 12) have increased gene expression of PDGFC and its activator PLAT and presymptomatic activation of the PDGF-CC pathway in SOD1 (G93A) mice leads to BSCB dysfunction. Decrease of Pdgfc expression in SOD1 (G93A) mice restored vascular barrier properties, reduced motor neuron loss and delayed symptom onset by up to 3 weeks. Similarly, lower expression levels of PDGFC or PLAT in motor neurons of sporadic ALS patients were correlated with older age at disease onset. PDGF-CC inhibition and restoration of BSCB integrity did not prevent capillary regression at disease end stage. Lower vessel density was found in spinal cords of sporadic ALS patients and the degree of regression in SOD1 (G93A) mice correlated with more aggressive progression after onset regardless of BSCB status. We conclude that PDGF-CC-induced BSCB dysfunction can contribute to timing of ALS onset, allow insight into disease origins and development of targeted novel therapies.

Entities:  

Keywords:  ALS; Blood–brain barrier; Cerebral blood flow; Neuroprotection; Small vessel disease

Mesh:

Substances:

Year:  2015        PMID: 26687981      PMCID: PMC4839168          DOI: 10.1007/s00401-015-1520-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  43 in total

1.  Platelet-derived growth factor is constitutively secreted from neuronal cell bodies but not from axons.

Authors:  M Fruttiger; A R Calver; W D Richardson
Journal:  Curr Biol       Date:  2000-10-19       Impact factor: 10.834

Review 2.  The neurobiology of amyotrophic lateral sclerosis.

Authors:  André Bento-Abreu; Philip Van Damme; Ludo Van Den Bosch; Wim Robberecht
Journal:  Eur J Neurosci       Date:  2010-06-07       Impact factor: 3.386

3.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen
Journal:  Nature       Date:  1993-07-22       Impact factor: 49.962

4.  Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis.

Authors:  A Leonardi; G Abbruzzese; L Arata; L Cocito; M Vische
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

5.  CCM1 regulates vascular-lumen organization by inducing endothelial polarity.

Authors:  Maria Grazia Lampugnani; Fabrizio Orsenigo; Noemi Rudini; Luigi Maddaluno; Gwénola Boulday; Francoise Chapon; Elisabetta Dejana
Journal:  J Cell Sci       Date:  2010-04-01       Impact factor: 5.285

6.  Platelet-derived growth factor C deficiency in C57BL/6 mice leads to abnormal cerebral vascularization, loss of neuroependymal integrity, and ventricular abnormalities.

Authors:  Linda Fredriksson; Ingrid Nilsson; Enming J Su; Johanna Andrae; Hao Ding; Christer Betsholtz; Ulf Eriksson; Daniel A Lawrence
Journal:  Am J Pathol       Date:  2012-01-09       Impact factor: 4.307

7.  Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man.

Authors:  Lindsey R Fischer; Deborah G Culver; Philip Tennant; Albert A Davis; Minsheng Wang; Amilcar Castellano-Sanchez; Jaffar Khan; Meraida A Polak; Jonathan D Glass
Journal:  Exp Neurol       Date:  2004-02       Impact factor: 5.330

8.  Tissue plasminogen activator is a potent activator of PDGF-CC.

Authors:  Linda Fredriksson; Hong Li; Christina Fieber; Xuri Li; Ulf Eriksson
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

9.  Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice.

Authors:  Ethan A Winkler; Jesse D Sengillo; Abhay P Sagare; Zhen Zhao; Qingyi Ma; Edward Zuniga; Yaoming Wang; Zhihui Zhong; John S Sullivan; John H Griffin; Don W Cleveland; Berislav V Zlokovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

10.  Identification of a neurovascular signaling pathway regulating seizures in mice.

Authors:  Linda Fredriksson; Tamara K Stevenson; Enming J Su; Margaret Ragsdale; Shannon Moore; Stefan Craciun; Gerald P Schielke; Geoffrey G Murphy; Daniel A Lawrence
Journal:  Ann Clin Transl Neurol       Date:  2015-05-01       Impact factor: 4.511

View more
  16 in total

Review 1.  PDGF/PDGFR axis in the neural systems.

Authors:  Susmita Sil; Palsamy Periyasamy; Annadurai Thangaraj; Ernest T Chivero; Shilpa Buch
Journal:  Mol Aspects Med       Date:  2018-02-06

Review 2.  Impaired tissue barriers as potential therapeutic targets for Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Xin Fang
Journal:  Metab Brain Dis       Date:  2018-04-22       Impact factor: 3.584

Review 3.  Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.

Authors:  Sebastian A Lewandowski; Linda Fredriksson; Daniel A Lawrence; Ulf Eriksson
Journal:  Pharmacol Ther       Date:  2016-08-12       Impact factor: 12.310

Review 4.  tPA Modulation of the Blood-Brain Barrier: A Unifying Explanation for the Pleiotropic Effects of tPA in the CNS.

Authors:  Linda Fredriksson; Daniel A Lawrence; Robert L Medcalf
Journal:  Semin Thromb Hemost       Date:  2016-09-27       Impact factor: 4.180

5.  Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss.

Authors:  Vladislav A Petyuk; Lei Yu; Heather M Olson; Fengchao Yu; Geremy Clair; Wei-Jun Qian; Joshua M Shulman; David A Bennett
Journal:  J Proteome Res       Date:  2021-04-26       Impact factor: 5.370

6.  Altered perivascular fibroblast activity precedes ALS disease onset.

Authors:  Anna Månberg; Nathan Skene; Folkert Sanders; Marta Trusohamn; Julia Remnestål; Anna Szczepińska; Inci Sevval Aksoylu; Peter Lönnerberg; Lwaki Ebarasi; Stefan Wouters; Manuela Lehmann; Jennie Olofsson; Inti von Gohren Antequera; Aylin Domaniku; Maxim De Schaepdryver; Joke De Vocht; Koen Poesen; Mathias Uhlén; Jasper Anink; Caroline Mijnsbergen; Hermieneke Vergunst-Bosch; Annemarie Hübers; Ulf Kläppe; Elena Rodriguez-Vieitez; Jonathan D Gilthorpe; Eva Hedlund; Robert A Harris; Eleonora Aronica; Philip Van Damme; Albert Ludolph; Jan Veldink; Caroline Ingre; Peter Nilsson; Sebastian A Lewandowski
Journal:  Nat Med       Date:  2021-04-15       Impact factor: 87.241

Review 7.  Tissue Plasminogen Activator in Central Nervous System Physiology and Pathology: From Synaptic Plasticity to Alzheimer's Disease.

Authors:  Tamara K Stevenson; Shannon J Moore; Geoffrey G Murphy; Daniel A Lawrence
Journal:  Semin Thromb Hemost       Date:  2021-12-23       Impact factor: 6.398

Review 8.  Major Histocompatibility Complex I Expression by Motor Neurons and Its Implication in Amyotrophic Lateral Sclerosis.

Authors:  Giovanni Nardo; Maria Chiara Trolese; Caterina Bendotti
Journal:  Front Neurol       Date:  2016-06-13       Impact factor: 4.003

9.  Neuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation.

Authors:  Karen-Sue B Carlson; Lan Nguyen; Kat Schwartz; Daniel A Lawrence; Bradford S Schwartz
Journal:  Front Cell Neurosci       Date:  2016-06-15       Impact factor: 5.505

10.  Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.

Authors:  Enming Joseph Su; Chunzhang Cao; Linda Fredriksson; Ingrid Nilsson; Christina Stefanitsch; Tamara K Stevenson; Juanjuan Zhao; Margret Ragsdale; Yu-Yo Sun; Manuel Yepes; Chia-Yi Kuan; Ulf Eriksson; Dudley K Strickland; Daniel A Lawrence; Li Zhang
Journal:  Acta Neuropathol       Date:  2017-07-19       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.